Journal
CURRENT MEDICINAL CHEMISTRY
Volume 27, Issue 22, Pages 3735-3752Publisher
BENTHAM SCIENCE PUBL LTD
DOI: 10.2174/0929867326666181203143422
Keywords
Ruthenium; DNA; DNA structural probe; cytotoxicity; binding mode; Cisplatin-based drugs; anticancer drugs
Funding
- National Natural Science Foundation of China [21541010]
- Beijing Natural Science Foundation [2182028]
- Open Research Fund Program of Key Laboratory of Cosmetic (Beijing Technology and Business University), China National Light Industry and Analytical and Measurements Fund of Beijing Normal University
Ask authors/readers for more resources
Ruthenium complexes have stood out by several mononuclear complexes which have entered into clinical trials, such as imidazolium [trans-RuCl4(1H-imidazole)(DMSO-S)] (NAMI-A) and ([Ru(II)(4,4'-dimethyl-2,2'-bipyridine)2-(2(2'-,2 '':5 '',2'''-terthiophene)-imidazo[4,5-f] [1,10]phenanthroline)](2+)) (TLD-1433), opening a new avenue for developing promising ruthenium-based anticancer drugs alternative to Cisplatin. Polynuclear ruthenium complexes were reported to exhibit synergistic and/or complementary effects: the enhanced DNA structural recognition and DNA binding as well as in vitro anticancer activities. This review overviews some representative polynuclear ruthenium complexes acting as DNA structural probes, DNA binders and in vitro anticancer agents, which were developed during last decades. These complexes are reviewed according to two main categories of homo-polynuclear and hetero-polynuclear complexes, each of which is further clarified into the metal centers linked by rigid and flexible bridging ligands. The perspective, challenges and future efforts for investigations into these exciting complexes are pointed out or suggested.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available